The purpose of the study is to evaluate the safety and tolerability of CEB-01 when used alongside standard cancer treatments. The study will involve children from birth to under 18 years of age who have these specific types of tumors. Participants will receive the new treatment in addition to their usual care, and the effects will be compared to those who receive only the standard treatment. The study will monitor for any side effects and how well the treatment works in preventing the cancer from coming back or spreading.

Throughout the study, researchers will collect information on the participants’ health and how their bodies process the treatment. This includes measuring the levels of the drug in the blood and observing any changes in the tumors. The study aims to provide valuable information on the potential benefits and risks of using CEB-01 in treating these childhood cancers.

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

The purpose of the study is to see if pasireotide can help patients with these cancers live longer without the disease getting worse. Patients will receive the medication through a deep intramuscular injection once a month. The study will compare the effects of pasireotide with a placebo to understand its effectiveness better. The trial will last for a period of time, during which patients will be monitored regularly to check on their health and the progress of their disease.

Participants in the study will include those who have already received standard treatments for their cancer and have shown stable disease or some improvement. The study aims to provide more information on whether pasireotide can be a beneficial maintenance treatment for these specific types of cancer. The ultimate goal is to improve the quality of life and survival rates for patients with synovial sarcoma and desmoplastic small round cell tumor.

The study will monitor patients who continue taking tazemetostat either alone or in combination with other approved or experimental medications. During the study, researchers will track any side effects that may occur and how well patients tolerate the medication over an extended period. The medication will be provided according to each patient’s previous treatment plan.

Participants will be monitored for various health measures, including their blood cell counts, kidney function, and liver function. The study will also track how long patients survive while receiving the treatment. This is an open-label study, which means all participants will receive the active medication, and there is no use of a placebo.

The purpose of the study is to evaluate how effective this new treatment is for patients with these specific types of cancer. Participants in the study will receive the treatment through an infusion, which means the medicine is given directly into the bloodstream through a vein. The study will follow participants over a period of time to monitor their response to the treatment and any side effects they may experience.

Throughout the study, researchers will collect information on how well the treatment works in shrinking the tumors and improving the patients’ health. They will also keep track of any adverse effects to ensure the safety of the participants. The study aims to provide valuable insights into the potential benefits of Afamitresgene autoleucel for treating these challenging cancers.

The purpose of the study is to evaluate how effective and safe this treatment is for patients with these specific types of cancer. Participants in the study will receive the GSK3377794 treatment, and some may also receive other anti-cancer agents. The study will monitor how the cancer responds to the treatment and any side effects that may occur. The treatment is given through an infusion, which means it is delivered directly into the bloodstream through a vein.

Throughout the study, participants will have regular check-ups to assess their health and the progress of the treatment. The study aims to provide valuable information on whether this new approach can help improve outcomes for patients with synovial sarcoma and myxoid/round cell liposarcoma. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment’s effectiveness and safety.

The purpose of the study is to monitor participants for any delayed side effects that might occur after receiving this cell therapy. Participants in this study have already received at least one infusion of the therapy and have completed a previous study or treatment program. The study will involve regular check-ups to observe any new health issues, such as new cancers, neurological disorders, autoimmune disorders, blood disorders, or infections that could be related to the cell therapy.

Throughout the study, participants will have their blood tested to check for specific DNA markers and to monitor the presence of the genetically modified cells. The study will also track any serious health events, including hospitalizations or unexpected illnesses, to ensure the safety and effectiveness of the treatment over time. The study is expected to continue until 2032, providing valuable information on the long-term effects of this innovative therapy.

The treatment being tested in this study is an IPX vaccine, which is an emulsion for injection. This vaccine is made up of specific proteins, including PERVI-FUS, PERVI-NEO, and 11902A. The purpose of the study is to see if this vaccine can help the body’s immune system, particularly T-cells, to respond to the cancer. T-cells are a type of white blood cell that play a crucial role in the immune response. The study will compare the effects of the vaccine to a placebo, which is a substance with no active ingredients.

Participants in the study will receive the vaccine over a period of time, with the maximum treatment period being 113 days. The study will monitor the participants’ immune response to the vaccine, as well as their overall health and quality of life during the treatment. The primary goal is to determine if the vaccine can successfully induce a T-cell response without causing unacceptable side effects. The study will also look at other factors, such as the participants’ event-free survival and overall survival at 180 days after the start of the study.